Abstract 5857: Trastuzumab deruxtecan resistance can be mediated by payload resistance or secondary extracellular ERBB2 mutations but sensitivity to HER2 tyrosine kinase inhibitors is maintained

曲妥珠单抗 酪氨酸激酶 细胞外 原癌基因酪氨酸蛋白激酶Src 医学 受体酪氨酸激酶 后天抵抗 癌症研究 激酶 内科学 生物 癌症 细胞生物学 受体 乳腺癌
作者
Monique B. Nilsson,Xiuning Le,Junqin He,Xiaoxing Yu,Xiaofang Huo,Vinod Kumar,Alissa Poteete,Qian Huang,Ralf Kittler,John V. Heymach
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:84 (6_Supplement): 5857-5857 被引量:2
标识
DOI:10.1158/1538-7445.am2024-5857
摘要

Abstract Among NSCLC patients, the most common HER2 mutation is the exon 20 insertion mutation, Y772dupYVMA, which accounts for over 40% of all HER2 mutations in lung cancer. Trastuzumab deruxtecan (T-DXd), a HER2 antibody-drug conjugate (ADC), received FDA approval for the treatment of HER2 mutant NSCLC yielding a confirmed objective response of 52% and a median duration of response of greater than 9 months. Unfortunately, patients that initially respond to T-DXd will eventually acquire resistance, and the mechanisms of resistance as well as effective targeting strategies to overcome resistance are not yet elucidated. We generated Ba/F3 cells expressing the HER2 YVMA insertion mutation with acquired resistance to T-DXd by culturing cells in T-DXd until resistance occurred. T-DXd resistant cells retained expression of HER2, but were resistant to the payload, deruxtecan, as well as other topoisomerase inhibitors. T-DXd resistant cells exhibited loss of topoisomerase I, a previously reported mechanism of topoisomerase inhibitor resistance. In parallel, we generated a PDX model of acquired T-DXd resistance and observed sustained expression of HER2 but loss of TOP1 in resistant tumors. T-DXd resistant cell lines were sensitive to payloads with alternate mechanisms of action including maytansine and likewise retained sensitivity to the HER2 ADC trastuzumab emtansine (T-DM1) which utilizes DM1 as a payload. Given that T-DXd resistant cells retained HER2 expression, we assessed whether they were sensitive to HER2 tyrosine kinase inhibitors (TKI). T-DXd resistant cells remained highly sensitive to HER2 TKIs including poziotinib, afatinib, BI-4142, and BI-1622. To investigate whether genomic alterations of HER2 could facilitate HER2 ADC resistance, we utilized the LentiMutate approach which employs an error-prone HIV-1 reverse transcriptase to produce a high frequency of mutations to identify resistance-associated mutations in cells treated with a HER2 ADC. Sequencing analysis revealed that resistant cells had an enrichment in point mutations within HER2 domain IV (D582N, F595C/S, E580K, C623Y), which includes the binding site of trastuzumab. To validate the impact of these mutations on HER2 ADC resistance, we generated cells expressing a HER2 exon 20 insertion in combination with the observed domain IV mutations. D582N and F695C/S co-mutations conferred resistance to T-DXd and T-DM1 but not to HER2 TKIs. These data demonstrate that resistance to T-DXd can be mediated by loss of sensitivity to the ADC payload in which case ADCs bearing payloads with alternate mechanisms of action as well as HER2 TKIs retain anti-tumor cell activity. Moreover, resistance to trastuzumab-based ADCs can also be mediated by secondary mutations within domain IV of HER2. However, these resistance mutations do not diminish HER2 TKI activity. Citation Format: Monique B. Nilsson, Xiuning Le, Junqin He, Xiaoxing Yu, Xiaofang Huo, Ashwani Kumar, Alissa Poteete, Qian Huang, Ralf Kittler, John Heymach. Trastuzumab deruxtecan resistance can be mediated by payload resistance or secondary extracellular ERBB2 mutations but sensitivity to HER2 tyrosine kinase inhibitors is maintained [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 5857.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
积极向上完成签到,获得积分0
刚刚
yhy发布了新的文献求助10
刚刚
刚刚
1秒前
2秒前
sunziyi发布了新的文献求助10
3秒前
3秒前
小马甲的应助被zdenglong采纳,获得10
4秒前
Monster完成签到,获得积分20
4秒前
4秒前
山北大花萼完成签到,获得积分10
5秒前
乐乐的应助被小饭采纳,获得10
5秒前
zch完成签到,获得积分10
6秒前
6秒前
秋风的应助被吱吱采纳,获得10
6秒前
7秒前
七七发布了新的文献求助10
7秒前
小董完成签到,获得积分20
7秒前
单薄冰安发布了新的文献求助10
7秒前
精明的如音完成签到,获得积分10
8秒前
酷波er的应助被楠楠采纳,获得10
8秒前
wanci的应助被echo采纳,获得10
8秒前
FOX发布了新的文献求助10
9秒前
9秒前
爆米花的应助被何文鑫采纳,获得10
9秒前
大模型的应助被wangfei采纳,获得10
9秒前
carpediem完成签到,获得积分10
9秒前
ZZt完成签到,获得积分10
9秒前
10秒前
chai发布了新的文献求助10
11秒前
worakls完成签到,获得积分10
11秒前
wg发布了新的文献求助10
11秒前
11秒前
门牙关注了科研通微信公众号
11秒前
慕青的应助被carpediem采纳,获得10
12秒前
13秒前
SCL987654321发布了新的文献求助10
13秒前
万能图书馆的应助被艾格采纳,获得10
13秒前
大模型的应助被sci采纳,获得30
15秒前
朴素香氛发布了新的文献求助10
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8188177
求助须知:如何正确求助?哪些是违规求助? 9575987
关于积分的说明 21844723
捐赠科研通 7785975
什么是DOI,文献DOI怎么找? 3435220
关于科研通互助平台的介绍 2559558
邀请新用户注册赠送积分活动 2482095